logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Therapeutic Area
    3. ENT & Ophthalmology

    ENT & Ophthalmology drugs

    FiltersReset Filters
    37 results

    • alphagan p

      (brimonidine tartrate)
      Allergan, Inc.
      Usage: ALPHAGAN P (brimonidine tartrate ophthalmic solution) is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

    • alrex

      (loteprednol etabonate)
      Bausch & Lomb Incorporated
      Usage: ALREX ophthalmic suspension is indicated for the temporary relief of signs and symptoms associated with seasonal allergic conjunctivitis.

    • amjevita

      (adalimumab-atto)
      Amgen Inc
      Usage: AMJEVITA is indicated for treating various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients, depending on the specific condition.

    • beovu

      (brolucizumab)
      Novartis Pharmaceuticals Corporation
      Usage: BEOVU® is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME).

    • bromsite

      (bromfenac)
      Sun Pharmaceutical Industries, Inc.
      Usage: BromSite (bromfenac ophthalmic solution) 0.075% is indicated for treating postoperative inflammation and preventing ocular pain in patients who have undergone cataract surgery.

    • cequa

      (cyclosporine)
      Sun Pharmaceutical Industries, Inc.
      Usage: CEQUA ophthalmic solution is indicated for increasing tear production in patients with keratoconjunctivitis sicca (dry eye) as a calcineurin inhibitor immunosuppressant.

    • cimerli

      (ranibizumab-eqrn)
      Coherus BioSciences Inc
      Usage: CIMERLI is indicated for treating neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.

    • combigan

      (brimonidine tartrate, timolol maleate)
      Allergan, Inc.
      Usage: COMBIGAN (brimonidine tartrate/timolol maleate) is indicated for reducing elevated intraocular pressure in patients with glaucoma or ocular hypertension. It serves as adjunctive or replacement therapy for those with inadequately controlled IOP, dosed twice daily for optimal effectiveness.

    • cosopt pf

      (dorzolamide hydrochloride and timolol maleate)
      Thea Pharma Inc.
      Usage: COSOPT® PF is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who do not adequately respond to beta-blockers. It is typically administered twice daily and offers a different IOP-lowering effect compared to standard therapies.

    • cyltezo

      (adalimumab-adbm)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: CYLTEZO is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients aged 2 and older.